{Reference Type}: Journal Article
{Title}: Quality control, safety assessment and preparation approaches of low molecular weight heparin.
{Author}: Yu Y;Song Y;Zhao Y;Wang N;Wei B;Linhardt RJ;Dordick JS;Zhang F;Wang H;
{Journal}: Carbohydr Polym
{Volume}: 339
{Issue}: 0
{Year}: 2024 Sep 1
{Factor}: 10.723
{DOI}: 10.1016/j.carbpol.2024.122216
{Abstract}: Low Molecular Weight Heparins (LMWHs) are well-established for use in the prevention and treatment of thrombotic diseases, and as a substitute for unfractionated heparin (UFH) due to their predictable pharmacokinetics and subcutaneous bioavailability. LMWHs are produced by various depolymerization methods from UFH, resulting in heterogeneous compounds with similar biochemical and pharmacological properties. However, the delicate supply chain of UFH and potential contamination from animal sources require new manufacturing approaches for LMWHs. Various LMWH preparation methods are emerging, such as chemical synthesis, enzymatic or chemical depolymerization and chemoenzymatic synthesis. To establish the sameness of active ingredients in both innovator and generic LMWH products, the Food and Drug Administration has implemented a stringent scientific method of equivalence based on physicochemical properties, heparin source material and depolymerization techniques, disaccharide composition and oligosaccharide mapping, biological and biochemical properties, and in vivo pharmacodynamic profiles. In this review, we discuss currently available LMWHs, potential manufacturing methods, and recent progress for manufacturing quality control of these LMWHs.